论文部分内容阅读
目的:探讨西酞普兰结合常规药物治疗老年前列腺增生伴抑郁患者的临床效果。方法:选取94例老年前列腺良性增生伴抑郁患者采用随机数字表法分为研究组和对照组各47例,两组均采取常规药物治疗前列腺增生,研究组加用西酞普兰治疗,对照组加用阿米替林治疗,两组疗程均为12周。结果:治疗前,研究组和对照组患者汉密尔顿抑郁量表(HAMD)、国际前列腺症状评分(IPSS)差异无统计学意义(P>0.05);治疗后,两组患者的HAMD、IPSS评分较治疗前均显著的降低(t=18.712,13.780,24.085,19.818;P<0.05);研究组患者的HAMD、IPSS评分均显著的低于对照组患者(t=2.833,-4.114;P<0.05);研究组患者的Qmax、RUV、前列腺体积组间比较差异无统计学意义(P>0.05);治疗过程中,研究组有13例患者发生不良反应、对照组有8例患者发生不良反应,研究组的不良反应发生率28.89%高于对照组的17.39%差异无统计学意义(P>0.05)。结论:西酞普兰结合治疗前列腺药物治疗老年前列腺增生伴抑郁患者在保证前列腺增生治疗效果的同时,具有更好的抗抑郁效果。
Objective: To investigate the clinical effect of citalopram combined with conventional drugs in the treatment of elderly patients with benign prostatic hyperplasia and depression. Methods: Ninety-four elderly patients with benign prostatic hyperplasia and depression were divided into study group and control group by random number table method, 47 cases in each group. Both groups were treated with conventional drugs for benign prostatic hyperplasia. The study group was treated with citalopram, while the control group Treatment with amitriptyline, two groups of treatment were 12 weeks. Results: There was no significant difference in Hamilton Depression Rating Scale (HAMD) and International Prostate Symptom Score (IPSS) between study group and control group before treatment (P> 0.05). After treatment, HAMD and IPSS scores of both groups were significantly higher than those of treatment group (T = 18.712,13.780,24.085,19.818; P <0.05). The scores of HAMD and IPSS in the study group were significantly lower than those in the control group (t = 2.833, -4.114, P <0.05). There were no significant differences in Qmax, RUV and prostate volume among the study group (P> 0.05). In the course of treatment, 13 patients in the study group had adverse reactions and 8 patients in the control group had adverse reactions. The study group The incidence of adverse reactions was 28.89% higher than 17.39% of the control group, with no significant difference (P> 0.05). Conclusion: Citalopram combined with prostatic drug treatment of benign prostatic hyperplasia with depression in patients with benign prostatic hyperplasia in the treatment of the same effect, with better antidepressant effect.